You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Novo and Lilly in battle over blood sugar, weight and heart health
Text:
Tommie Anderberg | [email protected]
Over the past two days, Eli Lilly and Novo Nordisk have presented three studies that could shape the future of treatments for type 2 diabetes, obesity and cardiovascular disease. Eli Lilly's orforglipron outperforms the approved...